Glenmark launches Covid drug After DCGI Approval

NEW DELHI: Glenmark launched antiviral drug ‘Favipiravir’ under the brand name ‘FabiFlu’, for the treatment of patients with mild and moderate Covid – 19. The Mumbai based drug company has said in a statement on Saturday.

According to the report, the drug firm had on Friday received manufacturing and marketing approval from the Drugs Controller General of India (DGCI). Post approval, the ‘FabiFlu’ is the first oral Favipiravir – approved medication for the treatment of Covid-19, the company said in a statement.

“This approval comes at a time when cases in the country are escalating like never before, which has put tremendous pressure on the health care”, said Glenn Saldanha, the chairman and managing director of Glenmark Pharmaceutics.

While, it hopes that availability of an effective treatment as ‘FabiFlu’ will considerably help alleviating this pressure and patients in India a much needed and timely therapy option, Glenn Saldanha added.